These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 1705008)

  • 21. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
    Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
    Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
    Lugo TG; Pendergast AM; Muller AJ; Witte ON
    Science; 1990 Mar; 247(4946):1079-82. PubMed ID: 2408149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia.
    Inokuchi K; Shinohara T; Futaki M; Hanawa H; Tanosaki S; Yamaguchi H; Nomura T; Dan K
    Genes Chromosomes Cancer; 1998 Nov; 23(3):227-38. PubMed ID: 9790503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.
    Reuther GW; Fu H; Cripe LD; Collier RJ; Pendergast AM
    Science; 1994 Oct; 266(5182):129-33. PubMed ID: 7939633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
    Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
    Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Sattler M; Scheijen B; Weisberg E; Griffin JD
    Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.
    Okuda K; D'Andrea A; Etten RA; Griffin JD
    J Clin Invest; 1997 Oct; 100(7):1708-15. PubMed ID: 9312168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.
    Hantschel O; Wiesner S; Güttler T; Mackereth CD; Rix LL; Mikes Z; Dehne J; Görlich D; Sattler M; Superti-Furga G
    Mol Cell; 2005 Aug; 19(4):461-73. PubMed ID: 16109371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The BCR/ABL hybrid gene.
    Groffen J; Heisterkamp N
    Baillieres Clin Haematol; 1987 Dec; 1(4):983-99. PubMed ID: 3332859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BCR gene encodes a novel serine/threonine kinase activity within a single exon.
    Maru Y; Witte ON
    Cell; 1991 Nov; 67(3):459-68. PubMed ID: 1657398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products.
    Allen PB; Morgan GJ; Wiedemann LM
    Baillieres Clin Haematol; 1992 Oct; 5(4):897-930. PubMed ID: 1308169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunologic characterization of the tumor-specific bcr-abl junction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    van Denderen J; van der Plas D; Meeuwsen T; Zegers N; Boersma W; Grosveld G; van Ewijk W
    Blood; 1990 Jul; 76(1):136-41. PubMed ID: 2194587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Bcr serine kinase by tyrosine phosphorylation.
    Liu J; Wu Y; Ma GZ; Lu D; Haataja L; Heisterkamp N; Groffen J; Arlinghaus RB
    Mol Cell Biol; 1996 Mar; 16(3):998-1005. PubMed ID: 8622703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
    Mitra A; Sasikumar K; Parthasaradhi BV; Radha V
    Biochim Biophys Acta; 2013 Jan; 1832(1):275-84. PubMed ID: 23124138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
    Campbell ML; Li W; Arlinghaus RB
    Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
    Sawyers CL
    Leuk Lymphoma; 1993; 11 Suppl 2():101-3. PubMed ID: 8124222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
    Liu J; Campbell M; Guo JQ; Lu D; Xian YM; Andersson BS; Arlinghaus RB
    Oncogene; 1993 Jan; 8(1):101-9. PubMed ID: 8423987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.
    Franz WM; Berger P; Wang JY
    EMBO J; 1989 Jan; 8(1):137-47. PubMed ID: 2496972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
    de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
    J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
    Gishizky ML; Cortez D; Pendergast AM
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.